Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute th... by Anna D. Ware (19688153)

Subjects:

Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disor... by Anna D. Ware (19688153)

Subjects:

Patient flowchart. by Anna D. Ware (19688153)

Subjects:

Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date. by Anna D. Ware (19688153)

Subjects:

Analysis of variance of the effects of clonal integration, <i>Bacillus subtilis</i>, and their interaction on growth and morphology of the basal portion, the apical portion and the... by Bing-Nan Zhao (21553401)

The growth of co-transformed cells in the peritoneal cavity alters their cellular gene expression to mirror that of PEL biopsies. by Mitchell Hayes (5334887)

ASFV-ΔI7L induces higher immune responses than does ASFV-WT in pigs. by Meilin Li (1832905)

Differential expression profiling in the ASFV-ΔI7L-infected primary porcine alveolar macrophages (PAMs) by RNA sequencing analysis. by Meilin Li (1832905)

pI7L suppresses the IFN-γ-triggered JAK-STAT signaling pathway. by Meilin Li (1832905)

The <i>I7L</i> gene is involved in ASFV pathogenicity in pigs. by Meilin Li (1832905)

The biological characteristics of the I7L protein (pI7L). by Meilin Li (1832905)

pI7L suppresses the IFN-<i>γ</i>-triggered JAK-STAT signaling pathway. by Meilin Li (1832905)

Percent viability and cytotoxicity of NHBE cells are significantly altered by PAA exposure. by Ellie S. Burns (21246537)

“…Percent viability significantly decreased with PAA concentration and between recovery times compared to controls. …”

pI7L inhibits the phosphorylation of STAT1 depending on its tyrosine at position 98. by Meilin Li (1832905)

Comparison of study groups based on patients’ variables before and after administration of study drugs. by Nadia Gul (249538)

Subjects:

Flow chart of patient’s recruitment and participation. by Nadia Gul (249538)

Subjects:

Comparative analyses of group 1 vs group 2 based on various patient characteristics. by Nadia Gul (249538)

Subjects:

Frequency of hypoglycemic episodes in group 1 vs group 2. by Nadia Gul (249538)

Subjects:

Demographics and baseline characteristics of patients. by Nadia Gul (249538)

Subjects:

Impact of group 1 and group 2 drugs on hyperglycemia based on HbA1c levels before and after 3 months of administration. by Nadia Gul (249538)

Subjects: